News B.R.A.I.N. Biotechnology Research and Information Network AG OTC Markets

Stocks

BRNB.F

DE0005203947

Environmental Services & Equipment

All News

Mentions Relevance

06-08	BRAIN Biotech AG, H1 2026 Earnings Call, May 28, 2026
05-28	BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
05-28	BRAIN Biotech : Management Statement 6M 2025/26 (BRAIN 6M 2025 26 Managementstatement)	PU
05-28	BRAIN Biotech : Half-year report as of 31 March 2026 (6M)	PU
05-28	BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance	EQ
03-23	BRAIN Biotech Secures European Patent for Genome-editing Technology	MT
03-23	BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology	EQ
03-11	Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG	EQ
03-09	BRAIN Biotech : Sustainability Report VSME for FJ 2023/24	PU
02-25	BRAIN Biotech : Management Statement 3M 2025/26 (BRAIN Managementstatement 3M 2025 26 )	PU
02-25	BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase® Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds	PU
02-25	BRAIN Biotech : Quarterly Statement as of 31 December 2025 (3M)	PU
02-25	BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds	EQ
02-25	BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
01-20	BRAIN Biotech AG, 2025 Earnings Call, Jan 14, 2026
01-14	BRAIN Biotech : Management Statement 12M 2024/25 (BRAIN Managementstatement 12M 2024 25)	PU
01-14	BRAIN Biotech : ESG Data Sheet 2023/24	PU
01-14	FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control	EQ
01-14	BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026	CI
01-14	BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2025	CI
09/09/25	BRAIN Biotech : Johan Jansén-Storbacka takes over as head of BRAINBiocatalysts' enzyme product business	PU
03/09/25	BRAIN Biotech AG Announces Executive Changes	CI
03/09/25	BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business	EQ
28/08/25	BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
28/08/25	BRAIN Biotech : Management Statement 9M 2024/25 (BRAIN Management Statement 9M24 25)	PU